Dienogest
Brand names: Natazia · Active ingredient: Dienogest
In short: Natazia™ is indicated for use by women to prevent pregnancy. The efficacy of Natazia in women with a body mass index (BMI) of > 30 kg/m2 has not been evaluated.
What is Dienogest used for?
Natazia™ is indicated for use by women to prevent pregnancy.
The efficacy of Natazia in women with a body mass index (BMI) of > 30
kg/m2 has not been evaluated.
⚠ Boxed warning (FDA's strongest warning)
Cigarette smoking increases the risk of serious
cardiovascular events from combination oral contraceptive (COC) use. This risk
increases with age, particularly in women over 35 years of age, and with the
number of cigarettes smoked. For this reason, COCs should not be used by women
who are over 35 years of age and smoke.
Dienogest dosage
Enter section text here
To achieve maximum contraceptive effectiveness, Natazia must be
taken exactly as directed. Take one tablet by mouth the same time every day.
Tablets must be taken in the order directed on the blister pack. Tablets should
not be skipped or intake delayed by more than 12 hours. For patient instructions
for missed pills, see FDA-Approved Patient Labeling.
Instruct the patient to begin taking Natazia on Day 1 of her
menstrual cycle (that is, the first day of her menstrual bleeding) . Instruct the patient
to use a non-hormonal contraceptive as back-up during the first 9 days.
For postpartum women who do not breastfeed or after a second trimester
abortion, Natazia may be started no earlier than 4 weeks postpartum. Recommend
use of a non-hormonal back-up method for the first 9 days. When combined oral
contraceptives (COCs) are used during the postpartum period, the increased risk
of thromboembolic disease associated with the postpartum period must be
considered. The possibility of ovulation and conception before starting COCs
should also be considered.
If the patient is switching from a combination hormonal method such as:
Another pill
Vaginal ring
Patch
Instruct her to take the first dark yellow pill on the first day of her
withdrawal bleed. She should not continue taking the pills from her previous
birth control pack. If she does not have a withdrawal bleed, rule out pregnancy
before starting Natazia.
If she previously used a vaginal ring or transdermal patch, she should start
using Natazia on the day the ring or patch is removed.
Instruct the patient to use a non-hormonal back-up method such as a condom
or spermicide for the first 9 days.
If the patient is switching from a progestin-only method such as a:
Progestin-only pill
Implant
Intrauterine system
Injection
Instruct her to take the first dark yellow pill on the day she would have
taken her next progestin-only pill or on the day of removal of her implant or
intrauterine system or on the day when she would have had her next injection.
Instruct the patient to use a non-hormonal back-up method such as a condom
or spermicide for the first 9 days.
In case of severe vomiting or diarrhea, absorption may not be
complete and additional contraceptive measures should be taken. If vomiting or
diarrhea occurs within 3-4 hours after taking a colored tablet, this can be
regarded as a missed tablet.
How to take Dienogest — instructions & advice from the label
See FDA-Approved Patient Labeling.
Counsel patients that cigarette smoking increases the risk of serious
cardiovascular events from COC use, and that women who are over 35 years old and
smoke should not use COCs.
Counsel patients that this product does not protect against HIV infection
(AIDS) and other sexually transmitted diseases.
Counsel patients on Warnings and Precautions associated with COCs.
Counsel patients to take one tablet daily by mouth at the same time every
day in the exact order noted on the blister. Instruct patients what to do in the
event pills are missed. See What Should I
Do if I Miss any Pills section or FDA-Approved Patient
Labeling.
Counsel women who are taking strong CYP3A4 inducers (for example,
carbamazepine, phenytoin, rifampicin, and St. John’s wort) not to choose Natazia
as their oral contraceptive due to the possibility of decreased contraceptive
efficacy.
Counsel patients to use a back-up or alternative method of contraception
when weak or moderate enzyme inducers are used with Natazia.
Counsel patients who are breastfeeding or who desire to breastfeed that COCs
may reduce breast milk production. …
Warnings & precautions
Do not take this medicine if: Do not prescribe Natazia to women who are known to have the
following:
A high risk of arterial or venous thrombotic diseases. Examples include
women who are known to:
Smoke, if over age 35
Have deep vein thrombosis or pulmonary embolism, now or in the past
Have cerebrovascular disease
Have coronary artery disease
Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for
example, subacute bacterial endocarditis with valvular disease, or atrial
fibrillation)
Have inherited or acquired hypercoagulopathies
Have uncontrolled hypertension
Have diabetes with vascular disease
Have headaches with focal neurological symptoms or have migraine headaches
with or without aura if over age 35
Undiagnosed abnormal genital bleeding
Breast cancer or other estrogen- or progestin-sensitive cancer, now or in
the past
Liver tumors, benign or malignant, or liver disease [see
Warnings and Precautions (
5.3
),
Use in Specific Populations (8.7) and
Clinical Pharmacology (12.3)].
Pregnancy, because there is no reason to use COCs during pregnancy .
Enter section text here
Stop COCs if an arterial or deep venous thrombotic (VTE) event
occurs. Although the use of COCs increases the risk of venous thromboembolism,
pregnancy increases the risk of venous thromboembolism as much or more than the
use of COCs. The risk of venous thromboembolism in women using COCs is 3 to 9
per 10,000 woman-years. The excess risk is highest during the first year of use
of a COC. Use of COCs also increases the risk of arterial thromboses such as
strokes and myocardial infarctions, especially in women with other risk factors
for these events. The risk of thromboembolic disease due to oral contraceptives
gradually disappears after COC use is discontinued. …
Dienogest side effects
The following serious adverse reactions with the use of COCs are
discussed elsewhere in the labeling:
Serious cardiovascular events and smoking
Vascular events
Liver disease
Adverse reactions commonly reported by COC users are:
Irregular uterine bleeding
Nausea
Breast tenderness
Headache
Because clinical trials are conducted under widely varying
conditions, adverse reaction rates observed in the clinical trials of a drug
cannot be directly compared to rates in the clinical trials of another drug and
may not reflect the rates observed in practice.
Two multicenter phase 3 clinical trials evaluated the safety and
efficacy of Natazia for pregnancy prevention. Both were non-comparative,
open-labeled, single-arm studies with a treatment duration up to 28 cycles. A
total of 1,867 women aged 18–50 were enrolled and took at least one dose of
Natazia.
Adverse Reactions Leading to Study Discontinuation:
11.5% of the women discontinued from the clinical trials due to an adverse
reaction; the most frequent adverse reactions leading to discontinuation were
metrorrhagia and irregular menstruation (1.9%), acne (1.2%), headache and
migraine (1.0%), and weight increase (0.7 %).
Common Treatment-Emergent Adverse Reactions (≥ 2%):
headache (including migraines) (13.2%), metrorrhagia and irregular menstruation
(8.0%), breast pain, discomfort or tenderness (6.6%), nausea or vomiting (6.5%),
acne (3.9%) and increased weight (2.8%). …
Drug interactions
Enter section text here
Interactions between oral contraceptives and other drugs may lead
to breakthrough bleeding and/or contraceptive failure. The following
interactions have been reported in the literature for COCs in general or were
studied in clinical trials with Natazia.
CYP3A4 Inducers: Drugs or
herbal products that induce certain enzymes, including CYP3A4, may decrease the
effectiveness of COCs or increase breakthrough bleeding. Some drugs or herbal
products that may decrease the effectiveness of hormonal contraceptives include
barbiturates, bosentan, felbamate, griseofulvin, oxcarbazepine, and topiramate.
Counsel women to use an alternative method of contraception or a back-up method
when moderate or weak enzyme inducers are used with COCs, and to continue
back-up contraception for 28 days after discontinuing the enzyme inducer to
ensure contraceptive reliability.
Dienogest is a substrate of cytochrome P450 (CYP) 3A4. Women who take
medications that are strong CYP3A4 inducers (for example, carbamazepine,
phenytoin, rifampicin, and St. John’s wort) should not choose Natazia as their
oral contraceptive while using these inducers and for at least 28 days after
discontinuation of these inducers due to the possibility of decreased
contraceptive efficacy. …
About this medicine
Natazia (estradiol valerate and estradiol valerate/dienogest)
tablets provide an oral contraceptive regimen consisting of 26 active
film-coated tablets that contain the active ingredients specified for each
tablet below, followed by two inert tablets:
2 dark yellow tablets each containing 3 mg estradiol valerate
5 medium red tablets each containing 2 mg estradiol valerate and 2 mg
dienogest
17 light yellow tablets each containing 2 mg estradiol valerate and 3 mg
dienogest
2 dark red tablets each containing 1 mg estradiol valerate
2 white tablets (inert)
Natazia also contains the excipients lactose monohydrate, maize starch, maize
starch pre-gelatinized, povidone 25, magnesium stearate, hypromellose, macrogol
6000, talc, titanium dioxide, and ferric oxide pigment, yellow, or ferric oxide
pigment, red.
The empirical formula of estradiol valerate is C23
H32 O3 and the chemical structure
is:
Estradiol Valerate
The chemical name of estradiol valerate is
Estra-1,3,5(10)-triene-3,17-diol(17ß)-,17-pentanoate. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 3fbcd7d8-cc53-4dbb-8edc-451acadc472c. Read the full official label on DailyMed.